



(12) **United States Patent**
Ocaranza Jeraldino et al.

(10) **Patent No.:** **US 9,511,120 B2**
(45) **Date of Patent:** **Dec. 6, 2016**

(54) **USE OF THE ANGIOTENSIN-(1-9) PEPTIDE OR DERIVATIVES THEREOF, USE OF VECTORS OVEREXPRESSION THE ACE2 ENZYME THAT PRODUCES ANGIOTENSIN-(1-9) FOR PREPARING MEDICAMENTS USEFUL FOR PREVENTING, REVERTING, INHIBITING AND/OR REDUCING HYPERTENSION AND/OR INDUCING VASODILATION**

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**
U.S. PATENT DOCUMENTS

7,468,390 B2* 12/2008 Ksander et al. 514/533

OTHER PUBLICATIONS

Ocaranza, M.P., et al "Protective Role of the ACE2/Ang-(1-9) Axis in Cardiovascular Remodeling," Int J Hypertens. 2012; pp. 1-12.*
C. D'iez-Freire, J. V'azquez, M. F. Correa De Adjounian et al., "ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR," Physiological Genomics, vol. 27, No. 1, pp. 12-19, 2006.*
Treatment definition of treatment by The Free Dictionary 2016 pp. 1-5.*
Diovan (Valsartan) Drug Information: Description, User Reviews, Drug Side Effects, Interactions Prescribing Information at RxList 2016 pp. 1-3.*
Chen, Zhenlong; et al., "Hydrolysis of Angiotensin Peptides by Human I-Converting Enzyme and the Resensitization of B2 Kinin Receptors," Hypertension (2005), 46(6), 1368-1373.*

* cited by examiner

Primary Examiner — Thomas S Heard
(74) *Attorney, Agent, or Firm* — Birch, Stewart, Kolasch & Birch, LLP

(57) **ABSTRACT**

The present invention is related to the use of the angiotensin-(1-9) peptide or peptides derived therefrom, which are biological or chemical analogs, for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation. Furthermore, this invention also comprises a vector overexpressing the homologous angiotensin-II converting enzyme (ACE2) for elevating the concentration in the blood and/or tissues of the angiotensin-(1-9) peptide. This vector may be adenovirus, retrovirus, lentivirus or adeno-associated virus containing the gene encoding for ACE2. This invention allows the administration of angiotensin-(1-9) or the derivatives thereof in oral form, injectable form, continuous infusion pump, or for increasing its levels in the body by means of the combined treatment with angiotensin-I converting enzyme inhibitors, with angiotensin-II receptor antagonists (ARA II), with Rho kinase inhibitors, with renin inhibitors, with L-type calcium channel antagonists and/or with diuretics.

24 Claims, 23 Drawing Sheets
(5 of 23 Drawing Sheet(s) Filed in Color)

(75) **Inventors:** **Maria Paz Ocaranza Jeraldino**, Santiago (CL); **Jorge Emilio Jalil Milad**, Santiago (CL); **Sergio Alejandro Lavandero González**, Santiago (CL); **Mario Martin Chiong Lay**, Santiago (CL); **Luis Fernando Michea Acevedo**, Santiago (CL)

(73) **Assignees:** **PONTIFICA UNIVERSIDAD CATÓLICA DE CHILE**, Santiago (CL); **UNIVERSIDAD DE CHILE**, Píso (CL)

(*) **Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) **Appl. No.:** **14/390,663**

(22) **PCT Filed:** **Apr. 5, 2012**

(86) **PCT No.:** **PCT/CL2012/000016**
§ 371 (c)(1),
(2), (4) **Date:** **Dec. 10, 2014**

(87) **PCT Pub. No.:** **WO2013/149355**
PCT Pub. Date: **Oct. 10, 2013**

(65) **Prior Publication Data**
US 2015/0190472 A1 Jul. 9, 2015

(51) **Int. Cl.**
A61K 38/22 (2006.01)
A61K 38/08 (2006.01)
A61K 38/48 (2006.01)
A61K 38/55 (2006.01)
A61K 45/06 (2006.01)

(52) **U.S. Cl.**
CPC **A61K 38/22** (2013.01); **A61K 38/085** (2013.01); **A61K 38/4813** (2013.01); **A61K 38/553** (2013.01); **A61K 38/556** (2013.01); **A61K 45/06** (2013.01)